Quality of life after immune suppressive therapy in aplastic anemia
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05731-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Iris N Lommerse und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Leiden University Medical Centre, Leiden, The Netherlands. i.n.lommerse@lumc.nl. Hauptthemen laut MEDLINE: Anemia, Aplastic, Quality of Life. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acquired aplastic anemia (AA) is a rare form of immune-mediated bone marrow failure, which can result in life-threatening infections or bleeding if left untreated. Treatment consists of either immune suppressive therapy (IST) or allogeneic stem cell transplantation (alloHSCT). While considerable research has been published regarding survival, response rate and toxicity of both treatments, knowledge on the impact on quality of life (QoL) is scarce. We used the recently developed AA-specific QoL questionnaire (QLQ-AA/PNH-54) to evaluate QoL in a single center cohort of AA patients who were successfully treated with IST. The 54 questions represent 12 different QoL domains. Results were analyzed for all patients and grouped based on hematologic response (complete response (CR) or partial response (PR)). Thirty-six successfully treated adult patients (15 in CR, 21 in PR) completed the questionnaire (median age 54 years, range 21–71; median time since last IST 5 years, range 0–41). Fatigue was experienced by 83% of patients. Even though total QoL scores did not significantly differ between patients with PR and CR (105 vs 92, p-value 0,17) there appeared to be a trend towards higher scores in patients with PR, especially in domains concerning psychological wellbeing. This trend was most clear in the domains fear of progression (2,12 in PR patients vs 1,73 in CR patients; p-value 0,08) and role functioning (2,22 vs 1,88; p-value 0,07). In conclusion, patients with AA continue to experience psychological and physical effects despite successful IST.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Leiden University Medical Centre, Leiden, The Netherlands. i.n.lommerse@lumc.nl.
- Department of Psychology, Leiden University Medical Centre, Leiden, The Netherlands.
- Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, Leiden, The Netherlands.
- Department of Hematology, HagaZiekenhuis, The Hague, the Netherlands.
- Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.
- Department of Hematology, Leiden University Medical Centre, Leiden, The Netherlands.
Zitieren
APA
Lommerse, I. N., Hinnen, C., van Vliet, L. M., Schubert, B., Panse, J., Halkes, C. J. M., & Tjon, J. M. (2024). Quality of life after immune suppressive therapy in aplastic anemia. Annals of Hematology. https://doi.org/10.1007/s00277-024-05731-x
Vancouver
Lommerse IN, Hinnen C, van Vliet LM, Schubert B, Panse J, Halkes CJM, et al. Quality of life after immune suppressive therapy in aplastic anemia. Annals of Hematology. 2024. doi:10.1007/s00277-024-05731-x
BibTeX
@article{Lommerse2024,
author = {Lommerse, Iris N and Hinnen, Chris and van Vliet, Liesbeth M and Schubert, Beke and Panse, Jens and Halkes, Constantijn J M and Tjon, Jennifer M-L},
title = {Quality of life after immune suppressive therapy in aplastic anemia},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05731-x}
}
EUVIMED